Seelos Therapeutics Stock Performance
SEEL Stock | USD 0.33 0.06 15.38% |
The entity has a beta of 1.38, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Seelos Therapeutics will likely underperform. Seelos Therapeutics has an expected return of -1.77%. Please make sure to validate Seelos Therapeutics treynor ratio and the relationship between the skewness and price action indicator , to decide if Seelos Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Seelos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in May 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Last Split Factor 1:30 | Dividend Date 2019-01-24 | Last Split Date 2023-11-28 |
1 | Seelos Therapeutics, Inc. Announces 4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules | 01/26/2024 |
2 | DHgate Partners with Seel to Offer On-time Delivery Guarantee | 02/22/2024 |
3 | Purchase by Smith Sandford D of 18200 shares of Seelos Therapeutics | 02/26/2024 |
4 | Is it Time to Dump Seelos Therapeutics Inc Stock After it Is Higher By 31.65 percent in a Week - InvestorsObserver | 02/27/2024 |
5 | Where Does Wall Street Think Seelos Therapeutics Inc Stock Will Go - InvestorsObserver | 03/06/2024 |
6 | Can Seelos Therapeutics Inc Stock Rise to the Top of Healthcare Sector Thursday - InvestorsObserver | 03/14/2024 |
7 | Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 | 03/19/2024 |
8 | Seelos Therapeutics swings and misses on ALS drug study - Green Market Report | 03/20/2024 |
9 | Merrimack Pharmaceuticals and Seelos Therapeutics Critical Comparison - Defense World | 04/12/2024 |
Begin Period Cash Flow | 15.5 M |
Seelos |
Seelos Therapeutics Relative Risk vs. Return Landscape
If you would invest 127.00 in Seelos Therapeutics on January 19, 2024 and sell it today you would lose (94.00) from holding Seelos Therapeutics or give up 74.02% of portfolio value over 90 days. Seelos Therapeutics is currently does not generate positive expected returns and assumes 8.2632% risk (volatility on return distribution) over the 90 days horizon. In different words, 73% of stocks are less volatile than Seelos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Seelos Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Seelos Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Seelos Therapeutics, and traders can use it to determine the average amount a Seelos Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2143
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | SEEL |
Estimated Market Risk
8.26 actual daily | 73 73% of assets are less volatile |
Expected Return
-1.77 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Seelos Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Seelos Therapeutics by adding Seelos Therapeutics to a well-diversified portfolio.
Seelos Therapeutics Fundamentals Growth
Seelos Stock prices reflect investors' perceptions of the future prospects and financial health of Seelos Therapeutics, and Seelos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Seelos Stock performance.
Return On Equity | -5.84 | ||||
Return On Asset | -1.8 | ||||
Operating Margin | (12.27) % | ||||
Current Valuation | 16.5 M | ||||
Shares Outstanding | 13.68 M | ||||
Price To Book | 15.10 X | ||||
Price To Sales | 2.87 X | ||||
Revenue | 2.2 M | ||||
Gross Profit | (46.65 M) | ||||
EBITDA | (40.44 M) | ||||
Net Income | (37.88 M) | ||||
Cash And Equivalents | 41.25 M | ||||
Cash Per Share | 0.39 X | ||||
Total Debt | 14.23 M | ||||
Debt To Equity | 0.73 % | ||||
Current Ratio | 3.60 X | ||||
Book Value Per Share | (3.42) X | ||||
Cash Flow From Operations | (23.91 M) | ||||
Earnings Per Share | (7.73) X | ||||
Market Capitalization | 5.27 M | ||||
Total Asset | 5.42 M | ||||
Retained Earnings | (252.63 M) | ||||
Working Capital | (33.52 M) | ||||
About Seelos Therapeutics Performance
To evaluate Seelos Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Seelos Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Seelos Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Seelos Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Seelos's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 64.50 | 96.59 | |
Return On Tangible Assets | (6.99) | (6.64) | |
Return On Capital Employed | 1.21 | 1.27 | |
Return On Assets | (6.99) | (6.64) | |
Return On Equity | 1.13 | 1.07 |
Things to note about Seelos Therapeutics performance evaluation
Checking the ongoing alerts about Seelos Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Seelos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Seelos Therapeutics generated a negative expected return over the last 90 days | |
Seelos Therapeutics has high historical volatility and very poor performance | |
Seelos Therapeutics has some characteristics of a very speculative penny stock | |
Seelos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 2.2 M. Net Loss for the year was (37.88 M) with loss before overhead, payroll, taxes, and interest of (46.65 M). | |
Seelos Therapeutics currently holds about 41.25 M in cash with (23.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Seelos Therapeutics has a poor financial position based on the latest SEC disclosures | |
Latest headline from news.google.com: Merrimack Pharmaceuticals and Seelos Therapeutics Critical Comparison - Defense World |
- Analyzing Seelos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Seelos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Seelos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Seelos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Seelos Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Seelos Therapeutics' stock. These opinions can provide insight into Seelos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Seelos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For more information on how to buy Seelos Stock please use our How to buy in Seelos Stock guide.Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Seelos Stock analysis
When running Seelos Therapeutics' price analysis, check to measure Seelos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seelos Therapeutics is operating at the current time. Most of Seelos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seelos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seelos Therapeutics' price. Additionally, you may evaluate how the addition of Seelos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Seelos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seelos Therapeutics. If investors know Seelos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seelos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.73) | Revenue Per Share 0.45 | Return On Assets (1.80) | Return On Equity (5.84) |
The market value of Seelos Therapeutics is measured differently than its book value, which is the value of Seelos that is recorded on the company's balance sheet. Investors also form their own opinion of Seelos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seelos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seelos Therapeutics' market value can be influenced by many factors that don't directly affect Seelos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seelos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seelos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seelos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.